Achilles Therapeutics PLC at Needham Healthcare Conference (Virtual) Transcript
Good morning and welcome to day two of the annual Needham and Company healthcare conference. My name is Gil Blum and I am a senior biotech analyst here at Needham & Company covering the immune oncology and gene therapy subsectors. It is my pleasure to have with me today Achilles' CEO, Iraj Ali. (Conference Instructions). And with that I will pass it on to Ali.
Thanks, Gil. Thanks, Needham, for the invitation and the opportunity to tell you a little bit more about Achilles Therapeutics. I'd ask those, in their own time, to take a look at the forward-looking statement at the top of our presentation and I'll jump into this story.
So, Achilles is developing precision medicines that -- for solid tumors targeting a wide range of cancers using a, what we call, clonal neoantigen reactive T cell or cNeT. But essential to the story is the ability to go after a novel class of target present in all tumor cells and absent from healthy tissue.
We really think this is
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
